Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire  by Damaj, Gandhi et al.
Biol Blood Marrow Transplant 20 (2014) 1349e1355Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgUpfront Allogeneic Stem Cell Transplantation after
Reduced-Intensity/Nonmyeloablative Conditioning for Patients
with Myelodysplastic Syndrome: A Study by the Société
Française de Greffe de Moelle et de Thérapie CellulaireGandhi Damaj 1, Mohammad Mohty 2, Marie Robin 3, Mauricette Michallet 4, Patrice Chevallier 5,
Yves Beguin 6, Stephanie Nguyen 7, Pierre Bories 8, Didier Blaise 9, Natacha Maillard 10,
Marie Therese Rubio 2, Nathalie Fegueux 11, Jerome Cornillon 12, Aline Clavert 13, Anne Huynh 14,
Lionel Adès 15, Anne Thiébaut-Bertrand 16, Olivier Hermine 17, Stephane Vigouroux 18,
Pierre Fenaux 15, Alain Duhamel 19, Ibrahim Yakoub-Agha 20,*
1Departement d’Hématologie, Centre Hospitalier Universitaire, Université de Caen, Faculté de Médecine, Caen, France
2Departement d’Hématologie, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Université Paris 6, Paris, France
3Departement d’Hématologie-Transplantation, Assistance Publique-Hôpitaux de Paris, Hôpital St. Louis, Université Paris 7, Paris, France
4Departement d’Hématologie, Centre Hospitalier Universitaire Lyon Sud, Lyon, France
5Departement d’Hématologie, Centre Hospitalier Universitaire, Nantes, France
6Departement d’Hematologie, Centre Hospitalier Universitaire and University of Liège, Belgium
7Departement d’Hématologie, Assistance Publique-Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Université Paris 6, Paris, France
8Departement d’Hématologie, Hôpitaux Universitaires de Strasbourg, France
9Departement d’Hématologie, Institut Paoli-Calmettes, Marseille, France
10Departement d’Hématologie, Centre Hospitalier Universitaire, Poitiers, France
11Departement d’Hématologie, Centre Hospitalier Universitaire, Montpellier, France
12Departement d’Hématologie, Centre Hospitalier Universitaire, Rennes, France
13Departement d’Hématologie, Centre Hospitalier Universitaire, Angers, France
14Departement d’Hématologie, Centre Hospitalier Universitaire Purpan, Toulouse, France
15Departement d’Hématologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Université Paris 13, Bobigny, France
16Departement d’Hématologie, Centre Hospitalier Universitaire et Unité Mixte de Recherche 5525 Centre National de Recherche Scientiﬁque-Université Joseph
Fournier, Grenoble, France
17Departement d’Hématologie, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Université Paris 5, Paris, France
18Departement d’Hématologie, Centre Hospitalier Universitaire, Bordeaux, France
19Departement de Biostatistics, Centre d’Etudes et de Recherche en Informatique Médicale, Centre Hospitalier Universitaire, Lille, France
20Departement d’Hématologie, Centre Hospitalier Régionale Universitaire, Lille, FranceArticle history:
Received 2 February 2014
Accepted 4 May 2014
Key Words:
Transplantation
Azacitidine
Best supportive care
MDSFinancial disclosure: See Acknowl
* Correspondence and reprint re
UAM allogreffes de CSH, CHRU, F-5
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Cytoreduction before allogeneic stem cell transplantation (allo-SCT) for patients with myelodysplastic syn-
dromes remains a debatable issue. After excluding patients who had received preconditioning induction
chemotherapy, we analyzed 128 consecutive patients with myelodysplastic syndrome who received reduced-
intensity or nonmyeloablative conditioning (RIC/NMA) allo-SCT. Among them, 40 received azacitidine (AZA)
before transplant (AZA group) and 88 were transplanted up front (best supportive care [BSC] group). At
diagnosis, 55 patients had intermediate 2 or high-risk scores per the International Prognostic Scoring System
and 33 had a high cytogenetic risk score. Progression to a more advanced disease before allo-SCT was
recorded in 22 patients. Source of stem cells were blood (n ¼ 112) or marrow (n ¼ 16) from sibling (n ¼ 78) or
HLA-matched unrelated (n ¼ 50) donors. With a median follow-up of 60 months, 3-year overall survival,
relapse-free survival, cumulative incidence of relapse, and nonrelapse mortality were, respectively, 53%
versus 53% (P ¼ .69), 37% versus 42% (P ¼ .78), 35% versus 36% (P ¼ .99), and 20% versus 23% (P ¼ .74), for the
AZA group and BSC group, respectively. Multivariate analysis conﬁrmed the absence of statistical differences
in outcome between the AZA and BSC groups, after adjusting for potential confounders using the propensityedgments on page 1355.
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G. Damaj et al. / Biol Blood Marrow Transplant 20 (2014) 1349e13551350score approach. The absence of cytoreduction before RIC/NMA allo-SCT did not seem to alter the outcome.
However, our results emphasize the need to perform prospective protocols to delineate the role of debulking
strategy and to identify subsets of patients who may beneﬁt from this approach.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION before transplantation, and disease status at transplant. In addition, weFigure 1. Flow chart for patient selection strategy. Patients whose ﬁles were
missing at least 1 of the following data were excluded: initial FAB/WHO
diagnosis, IPSS at diagnosis, before-transplantation treatment, WHO criteria,
and disease status at transplant.Allogeneic hematopoietic stem cell transplantation (allo-
SCT) remains the only potentially curative therapeutic
approach in patients with myelodysplastic syndrome (MDS).
Because the disease affects more often elderly than young
patients, reduced-intensity or nonmyeloablative condition-
ing (RIC/NMA), which gives similar results to myeloablative
conditioning with less toxicity, appeared to be more conve-
nient in this category of patients. Despite the beneﬁcial
effects of allo-SCT, these patients are at substantial risk of
relapse after transplant, especially in cases of RIC/NMA [1].
High disease burden at transplant has been shown to be
correlated with poor outcome and may increase the post-
transplant relapse risk [2-4].
Pretransplant induction-type chemotherapy has been
recommended in young patients when MDS was associated
with more than 5% marrow blasts [5]. The beneﬁt of induc-
tion chemotherapy before allo-SCT is not well established,
however. Although some studies suggested that upfront allo-
SCT with no prior cytoreduction gave the same results
as those in patients who received induction chemotherapy
[6-8], other studies suggested a beneﬁcial effect of induction
chemotherapy before transplant [2,4,9]. Thus, there is no
deﬁnitive evidence of a survival beneﬁt associated with
cytoreductive treatment before allo-SCT in MDS. We and
others showed that demethylating agents, which have em-
erged as the current standard of care for most patients with
intermediate 2 and high-risk MDS, were a valid “debulking”
approach and showed similar outcomes when compared
with induction chemotherapy [10-13].
The aim of the current study was to assess the impact of
best supportive care (BSC) compared with before transplant
treatment with azacitidine (AZA) on patient outcome after
allo-SCT following RIC/NMA for MDS. To perform this retro-
spective study, we used a propensity score-based approach
that can control for potentially confounding biases.
METHODS
The study was approved by the French Society of Bone Marrow Trans-
plantation and Cell Therapy board and conducted according to the Decla-
ration of Helsinki.
Patient Selection
Transplantation modalities were made as homogeneous as possible
using the following inclusion and exclusion criteria: (1) patients older than
18 years referred for ﬁrst allo-SCT after RIC or NMA according to the stan-
dard deﬁnition published by Bacigalupo et al. [14] and (2) source of stem cell
was marrow or blood from either a sibling or an HLA-A, -B, -Cw, -DR, and
-DQ identical unrelated donor at the allelic level (so-called 10/10). Patients
who received allo-SCT from an HLA-mismatched donor, cord blood, or
T celledepleted graft and patients with chronic myelomonocytic leukemia
were excluded.
Participating centers were asked to verify the data recorded for each
patient in the French Bone Marrow Transplantation Registry and to provide
additional information. Quality of the data was controlled using a comput-
erized search for discrepancy errors and vigorous onsite data veriﬁcation of
each ﬁle. HLA matching was cross-checked with the data from the French
Bone Marrow Donor Registry as previously described [15].
Consequently, 283 consecutive patients with MDS who underwent
allo-SCT between January 1999 and December 2009 in 24 French and
Belgian centers were identiﬁed. Twenty-seven patients were excluded
because their ﬁles lacked at least 1 of the following: initial French-
American-British (FAB)/World Health Organization (WHO) category or
International Prognostic Scoring System (IPSS) classiﬁcation, treatmentexcluded 128 patients who received induction-type chemotherapy or
cytoreduction treatment other than AZA. Based on local physicians’ de-
cisions, the 128 remaining patients received either best supportive care
(BSC group, n ¼ 88), which included blood transfusion, hormones, growth
factors (erythropoietin, granulocyte colony-stimulating factor), and
immunosuppressive treatment, or AZA alone (AZA group, n ¼ 40)
(Figure 1).Patient and Donor Characteristics and Transplantation Modalities
Morphological classiﬁcation, according to FAB and WHO classiﬁcations
[16,17], was documented as a separate variable at initial diagnosis and at time
of transplantation. IPSS at diagnosis was calculated [18], and all progressions
to more advanced disease between diagnosis and transplantation were
recorded. Responses to treatment and disease status at transplant were
reevaluated according to International Working Group 2006 criteria [19].
At diagnosis (Table 1), 42 of 128 patients (33%) had refractory anemia,
refractory anemia with ringed sideroblasts, or refractory cytopenia with
multilineage dysplasia, 46 (36%) patients had refractory anemia with excess
of blasts (RAEB-1), 34 patients (26%) had RAEB-2, and 6 patients (5%) had
RAEB in transformation/acute myeloid leukemia (with marrow blasts be-
tween 20% and 30%). Cytogenetic analysis was, according to IPSS classiﬁ-
cation [18], favorable, intermediate, and poor risk in 65 (51%), 30 (23%), and
33 patients (26%), respectively. IPSS was low or intermediate 1 in 73 patients
(lower risk category, 57%) or intermediate 2 and high in 55 patients (higher
risk category, 43%). Patients in the AZA group had signiﬁcantly higher IPSS at
diagnosis compared with the BSC group (P ¼ .003).
In the AZA group, the drug was started after a median time from diag-
nosis of 192 days (range, 38 to 941) and discontinued at a median time of
54 days before transplant (range, 6 to 438 days). The median number of AZA
cycles was 4.5 (range, 2 to 26). Themedian time from diagnosis to transplant
was 22.8 months. Thirty-three patients (26%) were transplanted before
7.3 months, 63 (49%) received allo-SCT between 7.3 and 22.8 months after
diagnosis, and 32 (25%) were transplanted after 26.7 months.
Table 2 depicts patients’ characteristics at transplant and trans-
plantation modalities according to treatment group before allo-SCT. Thus,
median age at transplant was higher in the AZA group compared with the
BSC group (60 versus 56 years; P ¼ .0001). Overall, 22 of 128 patients (17%)
had progressed to a more aggressive disease before transplantation: 7 pa-
tients (17.5%) in the AZA group and 15 (17%) in the BSC group. According to
International Working Group 2006 criteria [19], 29 patients (23%) were re-
sponders (including complete remission, partial remission, or marrow
complete remission): 26 patients (65%) in the AZA group and 3 (3%) in the
BSC group (P ¼ .0001).
Patients of the AZA group received more allo-SCT from an HLA-matched
unrelated donor than those of the BSC group (P ¼ .0001). There was no
Table 1
Patient Demographics and Clinical Characteristics at Diagnosis
Total
(n ¼ 128)
AZA Alone
(n ¼ 40)
BSC
(n ¼ 88)
P
Sex, n (%) .36
Male 78 (61) 22 (55) 56 (64)
Female 50 (39) 18 (45) 32 (36)
FAB/WHO, n (%) .028
RA/RARS/RCMD 50 (39) 8 (20) 42 (48)
RAEB-1 35 (27) 14 (35) 21 (24)
RAEB-2 37 (29) 15 (38) 22 (25)
RAEB-t/AML 6 (5) 3 (8) 3 (3)
IPSS, n (%) .003
Low/int-1 73 (57) 15 (36.5) 58 (66)
Int-2/high 55 (43) 25 (62.5) 30 (34)
Cytogenetics, n (%) .11
Favorable 65 (51) 20 (50) 45 (51)
Intermediate 30 (23) 6 (15) 24 (27)
High risk 33 (26) 14 (35) 19 (22)
Interval from diagnosis
to transplant, n (%)
.03
<7.3 mo 33 (26) 6 (15) 27 (31)
7.3-12.9 mo 31 (24) 15 (37.5) 16 (18)
12.9- 26.7 mo 32 (25) 12 (30) 20 (23)
26.7 mo 32 (25) 7 (17.5) 25 (28)
RA indicates refractory anemia; RARS, refractory anemia with ring side-
roblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB,
refractory anemia with excess blasts; int, intermediate.
Table 2
Patient Characteristics at Transplant and Transplantation Modalities
Total
(n ¼ 128)
AZA
(n ¼ 40)
BSC
(n ¼ 88)
P
Recipient age,
median (range)
58 (24-69) 60 (47-68) 56 (24-69) .0001
Donor age, median (range) 48 (19-77) 46 (19-68) 50 (21-77) .07
Sex mismatch,* n (%) 26 (20) 8 (20) 18 (20) .95
Progression
to more advanced
disease, n (%)
.95
No 106 (83) 33 (82.5) 73 (83)
Yes 22 (17) 7 (17.5) 15 (17)
Marrow blasts,
median (range)
5 (0-38) 3.8 (0-26) 6 (0-38) .18
Marrow blasts, n (%) .04
<5% 57 (45) 24 (60) 33 (38)
5% 65 (51) 16 (40) 49 (56)
Missing 6 (4) 0 6 (7)
Disease status, n (%) .0001
Respondersy 29 (23) 26 (65) 3 (3)
Nonresponders 99 (77) 14 (35) 85 (97)
Donor type, n (%) .0001
Sibling 78 (61) 14 (35) 64 (73)
HLA-matched unrelated 50 (39) 26 (65) 24 (27)
Stem cell source, n (%) .06
Marrow 16 (12.5) 2 (5) 14 (16)
PBSC 112 (87.5) 38 (95) 74 (84)
ATG, n (%) .17
No 43 (34) 10 (25) 33 (37)
Yes 85 (66) 30 (75) 55 (63)
TBI, n (%) .89
No 97 (76) 30 (75) 67 (76)
Yes 31 (24) 10 (25) 21 (24)
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because about 75% of patients received RIC in both groups and no patient
received 200-cGy total body irradiation alone.Conditioning, n (%) .66
NMA 29 (23) 10 (25) 19 (22)
RIC 99 (77) 30 (75) 69 (78)
GVHD prophylaxis, n (%) .66
CSA þ MTX 32 (25) 11 (27) 21 (24)
CSA þ other drugs 96 (75) 29 (73) 67 (76)
PBSC indicates peripheral blood stem cells; ATG, antithymocyte globulin;
TBI, total body irradiation; CSA, cyclosporine A; MTX, methotrexate.
* Sex mismatch is deﬁned as a male recipient who received graft from a
female donor.
y Responders included patients with complete or partial remission or
marrow complete remission.Statistical Analyses
The analysis was performed on the reference date of November 22, 2012.
Overall survival (OS) was deﬁned as the interval from allo-SCT to death,
regardless of the cause of death. Relapse-free survival (RFS) was deﬁned as
survival with no evidence of relapse. Relapse was deﬁned as the presence of
more than 5% marrow blasts and/or reappearance of major myelodysplastic
features associatedwith cytopenia (or worsening of previous cytopenia) and
evidence of autologous reconstitution when chimerism was available.
Nonrelapse mortality (NRM) was deﬁned as death resulting from the graft
procedure without evidence of relapse. Estimated 3-year event rates were
reported because the number of events beyond 3 years was insufﬁcient for
accurate estimates. Estimated 100-day event rates were assessed for acute
graft-versus-host disease (GVHD) and neutrophil and platelet engraftment.
For continuous variables, results were expressed as means and standard
deviations in cases of normal distribution and as medians and ranges
otherwise. The assumption of normality was assessed using the Shapiro-
Wilk test. Categorical variables were described by the frequencies and
percentages. The 2 before-transplant treatment groups (AZA and BSC) were
compared using the chi-square or the Fisher exact tests for categorical data.
For continuous variables, the ANOVA or Kruskal-Wallis test were applied
according to the distribution of the studied variable.
All censored criteria were calculated from the time of transplantation.
For OS, RFS, and acute GVHD, distributions over time were estimated by the
Kaplan-Meier product limit method. The log-rank statistic was used to test
the prognostic value of patient characteristics at transplant for the occur-
rence of the event. Before-transplant treatment and variables having a sig-
niﬁcance level (P value) less than .15 from the bivariate analyses were
introduced in a multivariable Cox regression, with backward selection at
level P < .15. Before-transplant treatment was always included in the se-
lection whatever its signiﬁcance level in bivariate analysis. Adjusted hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) were computed, and P  .05
was considered statistically signiﬁcant.
The occurrence of relapse, NRM, and chronic GVHDwas studied by using
competing risk methodology. For the events of relapse and GVHD, death
without experiencing the event was considered as a competing event. For
NRM, the competing event was relapse. The cumulative incidence of each
event was estimated using the Kalbﬂeish and Prentice method [20]. The
individual prognostic value of each variable was assessed by the Gray test
(comparison of cumulative incidence curves: bivariate analyses). Before-
transplant treatment and variables with P < .15 in the bivariate analyses
were introduced in a multivariate Fine and Gray model. Adjusted HR and
95% CIs were computed.Because our study was not randomized, we used a propensity score to
adjust P values for patients who received BSC and those who received AZA
[21]. The propensity score model included variables that might have inﬂu-
enced the outcome of allo-SCT; these included age of recipient, IPSS, cyto-
genetic risk groups, percentage of marrow blast and disease status at
transplant, donor type, donor age, stem cell source, time interval between
the diagnosis and the transplant, use of total body irradiation, and GVHD
prophylaxis. In multivariable analyses, P values for before-transplant treat-
ment are presented with and without propensity score adjustment. All
statistical analyses were performed with SAS software, version 9.2 (SAS
Institute, Cary, NC). For the Fine and Graymodel the R package “cmprsk”was
used (R Foundation for Statistical Computing, Vienna, Austria; http://
www.r-project.org/).
RESULTS
At the date of analysis (November 22, 2012), median
follow-up was 60 months (range, 36 to 143). All but 4 pa-
tients had obtained neutrophil engraftment after a median of
17 days (range, 0 to 70). Forty-four patients (34%) had
developed grades II to IV acute GVHD, including 16 patients
(13%) with grades III to IV. Of the 113 assessable patients who
survived more than 100 days, 60 (47%) had developed
chronic GVHD, including 36 (28%) with extensive grade. For
the whole patient group (n ¼ 128), the 3-year OS, RFS,
relapse rate, and NRM were 53%, 41%, 37%, and 22%,
respectively.
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Among all studied characteristics, at diagnosis, at trans-
plant, and transplantation modalities, the FAB/WHO classi-
ﬁcation, the interval from diagnosis to transplant, and the
donor type adversely impacted OS, with P values of .03, .009
and .04, respectively. RFS was adversely inﬂuenced by the
cytogenetic risk (P ¼ .02) as well as by the time interval be-
tween the diagnosis and transplant (P ¼ .003), which also
impacted the NRM (P ¼ .01). The IPSS at diagnosis negatively
affected the relapse risk (P ¼ .04) and tended to inﬂuence OS
(P ¼ .05). Cytogenetics adversely impacted the relapse risk
(P ¼ .003).
As shown in Table 3, none of the following variables
seemed to inﬂuence the outcome of patients: gender and
recipient age, sex mismatch, donor age, stem cell source,
recipient and conditioning regimen modalities (i.e. antithy-
moglobulin or total body irradiation), GVHD prophylaxis,
donor/recipient cytomegalovirus status, progression to more
advanced disease at time of transplant, marrow blasts, or
disease status at transplant.
Outcome According to Before-Transplant Treatment
In patients treated with AZA and patients transplanted
upfront after BSC, 3-year OS was 53% versus 53% (P ¼ .69), 3-
year RFS was 37% versus 42% (P ¼ .78), cumulative incidence
of relapse was 35% versus 36% (P ¼ .99), and NRM was 20%
versus 23% (P ¼ .74), respectively (Figure 2).
Multivariate Analysis
Because treatment with AZA or management of patients
with BSC before allo-SCT was not allocated through
randomization, we used a propensity score-based approach
for the comparison of outcomes between patients in the AZA
and BSC groups as described above in Statistical Analyses.
The time interval between diagnosis and transplant was
found to have an impact on outcome. Therefore, being
transplanted after more than 26.7 months adversely
inﬂuenced OS (HR ¼ 2.28; 95% CI, 1.31 to 3.95; P ¼ .003),
RFS (HR ¼ 2.39; 95% CI, 1.44 to 3.96; P ¼ .0007), and
NRM (HR ¼ 2.55; 95% CI, 1.18 to 5.39; P ¼ .017). As expected,
high-risk cytogenetics had a detrimental impact on RFS
(HR ¼ 1.99; 95% CI, 1.18 to 3.38; P ¼ .01) and cumulative
incidence of relapse (HR ¼ 3.05; 95% CI, 1.68 to 5.53;
P ¼ .0002). Unrelated donor had a detrimental impact on OS
(HR ¼ 1.78; 95% CI, 1.01 to 3.14; P ¼ .044) and NRM
(HR ¼ 2.30; 95% CI, 1.01 to 5.24; P ¼ .047). Disease status
(nonresponders versus responders) at transplant adversely
inﬂuenced NRM (HR ¼ 3.29; 95% CI, 1.13 to 9.58; P ¼ .029).
The type of treatment before allo-SCT had no impact on
the incidence and severity of either acute or chronic GVHD.
Donor type was the only factor that inﬂuenced acute GVHD
development (HR ¼ 1.66; 95% CI, 1.03 to 2.69; P ¼ .037).
Multivariate analysis conﬁrmed the absence of signiﬁcant
differences between AZA and BSC groups in terms of OS
(HR¼ 1.27; 95% CI, .78 to 2.34; P¼ .445), RFS (HR¼ 1.04; 95%
CI, .61 to 1.75; P ¼ .897), relapse (HR ¼ 1.15; 95% CI, .62 to
2.13; P ¼ .653), and NRM (HR ¼ 1.56; 95% CI, .64 to 3.85;
P ¼ .325). As shown in Table 4, the same results were ob-
tained after propensity adjustment.
DISCUSSION
In this series, patients with MDS who underwent upfront
RIC allo-SCT without prior cytoreduction had similar out-
comes compared with those who received AZA as a pre-
conditioning treatment in terms of OS, RFS, cumulativeincidence of relapse, and NRM. These results were conﬁrmed
after adjustment with propensity score that included main
patients and disease characteristics and transplantation
modalities.
To our knowledge, our study is the ﬁrst to investigate the
effect of AZA before transplant as compared with BSC in
patients undergoing RIC/NMA allo-SCT for MDS. Few studies
have addressed the impact of pretransplant AZA in MDS
patients [11,13]. In these studies, data interpretation is
difﬁcult because of the heterogeneity of pretransplant char-
acteristics regarding the treatment (AZA and/or che-
motherapy or BSC) or the conditioning regimens that were
either myeloablative or RIC/NMA according to standard
deﬁnitions [14].
The incidence of post-transplant relapse appears to be
higher after RIC/NMA than after myeloablative conditioning
[5,22-24]. Because reducing the bulk of the disease before
transplant is thought to be a strategy to decrease the inci-
dence of post-transplant relapse [4,5,25], we deliberately
chose to restrict our study to patients who received a RIC/
NMA regimen, hypothesizing that before-transplant treat-
ment could have a signiﬁcant impact on outcome in this
setting. We also wanted to speciﬁcally investigate the impact
of AZA before transplant compared with BSC given that AZA
showed similar outcomes when compared with induction
chemotherapy [10-13].
To make the study population as homogeneous as
possible, we included only patients who received allo-SCT
from an HLA sibling or HLA-allelically matched unrelated
donor (10/10). This donor selection may explain in part the
higher survival rate observed in the BSC group when
compared with the ﬁndings reported by Lim et al. [26], for
instance. Indeed, the population of this latter study was
different from ours in that Lim et al. included 25% of patients
with secondary acutemyeloid leukemia, 34%weremore than
60 years old, and some patients had received allo-SCT from
unrelated mismatched donors. Of note, the OS rate observed
in our current study is similar to that previously reported in
allo-SCTs from sibling [6,7,15] or HLA-matched unrelated
donors [15].
Given the retrospective nature of our study, we used
propensity score adjustment to accurately identify the im-
pact of BSC and AZA on patient outcome by balancing the
covariates in the 2 groups and reducing bias when treatment
assignment was not random [21]. After adjustment, OS, RFS,
cumulative incidence of relapse, and NRM were not statis-
tically different between the 2 groups of patients.
In an attempt to identify a subset of patients that could
beneﬁt from AZA, we analyzed the 3-year OS in the AZA
group according to disease status at transplant. Although the
difference in OS did not reach the signiﬁcance threshold,
responders to AZA (n ¼ 26) seemed to do better than non-
responders (n ¼ 14) (62% versus 36%, respectively; P ¼ .08).
Therefore, if there is an indication for stabilizing the disease
while waiting for the transplant, we suggest restricting the
use of AZA to patients who are likely to respond to this drug.
Indeed, some factors have been identiﬁed to inﬂuence the
response to AZA, such as age, cytogenetics, molecular ab-
normalities, and hyperferritinemia [27-30]. New therapeutic
strategies combining AZA and other drugs known to have an
effect in MDS have been suggested [31,32]. However, this
latter approach is to be used with caution in candidates for
allo-SCT because the combination of AZA and induction-type
chemotherapy as debulking treatment was reported to lead
to less satisfactory outcomes in a retrospective study [10].
Table 3
Bivariate Analysis by Key Subsets: 3-Year OS and Event-Free Survival, Relapse, and NRM Rates and P Values
No. of
Patients
OS RFS Relapse NRM
% P (Log-rank) % P (Log-rank) % P (Gray [Cumulative
Incidence])
% P (Gray [Cumulative
Incidence])
Sex .84 .83 .46 .70
Male 78 52.6 41.9 33.3 23.1
Female 50 54.0 40.8 40.0 20.0
Patient age .30 .08 .27 .68
58 yr 64 57.8 49.6 31.3 20.3
>58 yr 64 48.4 33.5 40.6 23.4
FAB/WHO .03 .21 .10 .77
RA/RARS/RCMD 50 71.4 56.5 22 25
RAEB-1 35 39.1 35.3 16 25
RAEB-2 37 52.9 33.6 41 17
RAEB-t/AML 6 33.3 25.0 33 33
IPSS .05 .12 .04 .43
Low/int-1 73 60.3 47.9 28.8 24.6
Int-2/high 55 43.6 32.9 45.5 18.2
Cytogenetics .07 .02 .0003 .13
Favorable/int 95 57.9 47.6 27.4 25.3
High risk 33 39.4 22.2 60.6 12.1
Sex mismatch* .91 .58 .41 .89
No 102 52.9 41.3 37.3 21.6
Yes 26 53.9 41.5 30.8 23.1
Progression to more advanced disease .76 .67 .32 .68
No 106 53.8 41.6 34.0 22.6
Yes 22 50 40.9 45.5 18.2
Marrow blasts .23 .14 .10 .71
<5% 57 57.9 44.3 28.1 24.6
5% 63 47.6 37.3 42.9 20.6
Treatment before allo-SCT .69 .78 .99 .74
BSC 88 53.4 42.0 36.4 22.7
AZA alone 40 52.5 36.5 35.0 20.0
Interval from diagnosis to transplant .009 .003 .38 .01
<26.7 mo 96 59.4 49.6 33.3 16.7
26.7 mo 32 34.4 17.0 43.8 37.5
Disease statusy .48 .36 .91 .26
Responders 29 62.1 34.6 34.5 13.8
Nonresponders 99 50.5 40.4 36.4 24.2
Donor age .47 .07 .06 .81
<48 yr 64 57.8 51.4 28.1 21.9
48 yr 63 49.2 32.5 44.4 20.6
Donor type .04 .57 .31 .07
Sibling 78 59.0 43.0 39.7 16.7
HLA-matched unrelated 50 44.0 39.3 30.0 30.0
Stem cell source .23 .31 .81 .63
Marrow 16 62.5 50.0 37.5 18.8
PBSC 112 51.8 39.9 35.7 22.3
GVHD prophylaxis .40 .23 .59 .11
CSA þ MTX 32 56.2 45.5 40.6 12.5
CSA þ other drugs 96 52.1 40.1 34.4 25
CMV recipient serostatus .73 .54 .17 .36
Negative 56 50 39.6 42.9 17.9
Positive 72 55.6 43.3 30.6 25.0
CMV donor serostatus .80 .60 .32 .53
Negative 61 54.1 42.2 32.8 24.6
Positive 67 52.2 41.0 38.8 19.4
ATG .28 .36 .37 .52
No 43 44.1 36.8 41.8 25.6
Yes 85 57.6 44.1 32.9 20
TBI .14 .24 .26 .85
No 97 55.7 43.4 34.0 21.6
Yes 31 45.2 36.0 41.9 22.6
RA indicates refractory anemia; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; AML, acute myeloid leukemia;
RCMD, refractory cytopenia with multilineage dysplasia; int, intermediate; PBSC, peripheral blood stem cells; CSA, cyclosporine A; MTX, methotrexate; CMV,
cytomegalovirus; ATG, antithymocyte globulin; TBI, total body irradiation.
* Sex mismatch is deﬁned as a male recipient who received graft from a female donor.
y Responders included patients with complete or partial remission or marrow complete remission.
G. Damaj et al. / Biol Blood Marrow Transplant 20 (2014) 1349e1355 1353Still, prospective studies are warranted to investigate more
precisely not only prognostic factors of response but also the
optimum schedule of AZA perfusion to enhance response
rate and, thus, favorably impact on patient outcome.In line with what has been already reported [6,25], we
observed that delaying the transplant was the foremost in-
dependent factor with a detrimental impact on OS, RFS, and
NRM. The “wait-and-see” attitude in low-risk IPSS MDS
Figure 2. Kaplan-Meier estimates of 3-year OS, RFS, 3-year cumulative incidence of relapse, and NRM in 128 patients, according to treatment received before
transplant. ( ) AZA-group, ( ) BSC-group.
G. Damaj et al. / Biol Blood Marrow Transplant 20 (2014) 1349e13551354patients deserves to be revisited [33]. Indeed, factors such as
transfusion dependency, cytogenetics, medical comorbidity,
and WHO histologic subtype should all be considered when
deciding on the role and the timing of transplantation for
these patients [34].
A limitation of this study is its retrospective nature with
possible selection bias as a result of the impossibility of ac-
counting for patient dropout (either complication fromTable 4
Multivariate Analyses
Characteristics 3-Year OS 3-Year RFS
HR 95% CI P* HR 95%
Cytogenetics
Low/int 1
High risk 1.99 1.18
Prior treatment
AZA alone 1 .45 1
BSC vs AZA alone 1.27 .68-2.34 .64* 1.04 .61
Donor type
Sibling 1
HLA-matched unrelated 1.78 1.01-3.14 .044
Disease status
Responders
Nonresponders
Interval from diagnosis to transplant
<26.7 mo 1 1
26.7 mo 2.28 1.31-3.95 .003 2.39 1.44
Int indicates intermediate; CSA, cyclosporine A; MTX, methotrexate.
Because our studywas not randomized, we used a propensity score to adjust P value
score model included variables that might have inﬂuenced the outcome of allo-S
marrow blast and disease status at transplant, donor type, donor age, stem cell sour
irradiation, and GVHD prophylaxis. Before-transplant treatment and variables havi
the multivariate model: *P by propensity score.before-transplant treatment in the AZA group or rapid pro-
gression to acutemyeloid leukemia in both groups). Thus, the
result of this homogeneous study, in the absence of data from
prospective randomized studies regarding the usefulness of
debulking treatment before transplantation in myelodys-
plastic patients, could represent a ﬁrst step forward to an
accurate answer to this question. Although AZA is thought to
have an immunomodulation effect that could inﬂuence3-Year Relapse 3-Year NRM
CI P* HR 95% CI P* HR 95% CI P*
1
-3.38 .01 3.05 1.68-5.53 .0002
.90 1 .65 1 .33
-1.75 .99* 1.15 .62-2.13 .75* 1.56 .64-3.85 .97*
1
2.30 1.01-5.24 .047
1
3.29 1.13-9.58 .029
1
-3.96 .0007 2.52 1.18-5.39 .017
s for patients who received BSC and those who received AZA. The propensity
CT, including age of recipient, IPSS, cytogenetic risk groups, percentage of
ce, time interval between the diagnosis and the transplant, use of total body
ng a signiﬁcance level of P < .15 in the bivariate analyses were introduced in
G. Damaj et al. / Biol Blood Marrow Transplant 20 (2014) 1349e1355 1355GVHD development [35], we did not observe any difference
between the 2 groups in terms of acute and chronic GVHD.
In conclusion, the absence of cytoreduction by AZA before
allo-SCT did not alter the outcome of patients with MDS.
However, there is a clear need for prospective trials to
identify a subset of patients whomay beneﬁt from debulking
treatment before allo-SCT according to the newest prog-
nostic factors.
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